Benjamin M. Ellingson, Ph.D.
|
|
- Magnus Webb
- 5 years ago
- Views:
Transcription
1 Simultaneous ph- and Oxygen-Weighted Metabolic Imaging of Brain Tumors using Multi-Echo Amine Chemical Exchange Saturation Transfer (CEST) Echo Planar Imaging Benjamin M. Ellingson, Ph.D. Associate Professor of Radiology, Psychiatry, Bioengineering and Biomedical Physics UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers Depts. of Radiological Sciences and Psychiatry David Geffen School of Medicine at UCLA March 15, 2018
2 Disclosures MedQIA, LLC Paid Consultant, Ad Board Hoffman La-Roche/Genentech Paid Consultant, Research Grant, Ad Board Agios Pharmaceuticals Paid Consultant, Ad Board Insys Paid Consultant, Ad Board OmniOx Paid Consultant, Ad Board Nativis Paid Consultant, Ad Board Bristol Myers Squibb Paid Consultant Siemens Paid Consultant, Research Grant Exelixis Paid Consultant Janssen Pharmaceuticals Research Grant National Brain Tumor Society Research Grant American Cancer Society Research Grant Medicenna Paid Consultant NIH/NCI CISC Paid Consultant Imaging Endpoints Paid Consultant Novogen Paid Consultant, Ad Board
3 WHO Classification of Cancer WHO = World Health Organization Grade: How abnormal cells look under the microscope How quickly they are likely to grow or spread Also called differentiation I-IV from least to most malignant/differentiated I: Well differentiated (low Grade) II: Moderately differentiated (Intermediate Grade) III: Poorly differentiated (High Grade / Malignant) IV: Undifferentiated (High Grade / Malignant)
4 WHO Classification of Cancer Stage: Extent or severity of the cancer Tumor size, number of tumors, distance of lesion from primary cancer site (mets?), lymph node involvement
5 Brain Cells Neurons Direct Communication Oligodendrocytes Myelination Increases signal transduction Astrocytes Support Cells Communication? Nourishment (BBB)
6 Brain Cancer - Gliomas Brain Cancer Does Not Metastasize (No Staging, Only Grading) Neuroblastomas & Epidemoma Oligodendrogliomas Oligodendroglioma (WHO II) Anaplastic Oligodendroglioma (WHO III) Astrocytomas Astrocytoma (WHO II) Anaplastic Astrocytoma (WHO III) Mixed Gliomas Astrocytoma and Oligodendroglioma Glioblastoma (GBM) - WHO IV
7 Glioma Biology Glioblastoma (WHO IV)
8 Brain Cancer Incidence
9 Glioma Incidence Central Brain Tumor Registry United States, 2012
10 Glioma Incidence Central Brain Tumor Registry United States, 2012
11 Poor Prognosis in Glioblastoma AVAglio: Phase III Comparison of Chemoradiation with or without Bevacizumab Percent Survival Bevacizumab (N = 404) Placebo (N = 394) Log-rank, P = HR = Stupp, N Engl J Med, Overall Survival [Days] Ellingson, ASCO, 2016 Median Overall Survival Radiotherapy = 12 months Radiotherapy + TMZ = 14 months Radiotherapy + Bev Upfront = 18 months Radiotherapy + Placebo Recurrence] = 18 months
12 Glioma Biology Brat & Mapstone, Ann Int Med, 2003
13 Use of Imaging for Measuring Therapeutic Response Serial biopsies are not possible or safe (few pathology-confirmed responses) MRI (and PET) imaging are routinely used for clinical monitoring and response assessment MRI has exquisite soft tissue contrast, no ionizing radiation, and a variety of flavors for evaluating anatomy and physiology
14 Overview of Basic MRI Sequences for GBM Evaluation T2-Weighted MRI T2-Weighted FLAIR MRI Diffusion-Weighted MRI (DWI) Pre-Contrast T1-Weighted MRI Post-Contrast T1-Weighted MRI Pre-Contrast T1w Post-Contrast T1w NOTE: ALL MRI TECHNIQUES ARE SURROGATES OF TUMOR BIOLOGY - All techniques measure some aspect of tumor biology, not tumor cells directly - All MRI techniques measure impact on extracellular water protons ** Limited Physiologic Information About the Tumor
15 Tumor Angiogenesis Aggressive cancers are characterized by angiogenesis Essential for progression from low- to high-grade & clear correlation between degree of neovascularization and malignancy (Russell, Surg Neurol, 2009; Lean, Cancer, 1996; Wesseling, Hum Pathol, 1998) After infiltration/migration, growth factors (e.g. VEGF) cause co-option of local vasculature (Loges, Cancer Cell, 2009) Once tumor bed has reached a critical size (1-2mm diameter) angiogenesis is initiated (Jain, Nat Rev Neurosci, 2007; Plate, 1995; Rampling, 1994) Angiogenesis Foundation
16 Contrast Enhancement as a Surrogate of Tumor These new vessels are leaky and inefficient (Yuan, Cancer Res, 1994; Hobbs, PNAS, 1998; Monsky, Cancer Res, 1999) Contrast agents that highlight BBB permeability 1941 First case using X-ray and Diodrast (sodium iodide) to highlight vasculature published in Radiology 1946 Study with 130 patients with cerebral masses published T1 Pre T1 Post
17 Contrast Enhancement as a Surrogate of Tumor Confirmed (surgically) to contain most aggressive tumor (Butler, 1978; Lilja, 1981; Berger, 1983; Kelly, 1987; Earnest, 1988; Dean, 1990; Barajas, 2010; Kubben, 2012 ) Cancer Info Database: 28 June 2012
18 Warburg Effect (Aerobic Glycolysis)
19 The Tumor Milieu - Perfusion, Oxygen Metabolism, and ph As tumors become larger, regions away from vasculature become hypoxic and more acidic Jain et al., Nat Rev Neurosci 2007
20 Hypoxia, Acidity, and Malignant Transformation Perfusion
21 Hypoxia, Acidity, and Malignant Transformation
22 Glutamine as a Primary Fuel in Tumor Cells Glutamine is a major fuel source for malignant tumors (Souba, Annals of Surgery, 1993; Kovacevic, Cancer Res, 1972; Medina, Mol Cell Biochem, 1992) Circulating concentrations mm and as high as 20mM Tumor cells act like a glutamine trap (Kovacevic, Cancer Res, 1972) Demand is so high transport systems are amplified (Medina, Mol Cell Biochem, 1992) Kaelin Jr & Thompson, Nature 456: (2010)
23 ph-weighted MRI Using Amine CEST Mechanism: Targeted off-resonance saturation of fast exchanging amine protons (3.0ppm) on amino acids (glutamine) results in ph-dependent attenuation of the water proton MR signal
24 Chemical Exchange Saturation Transfer (CEST) Imaging CEST imaging uses a soft RF pulse to saturate longitudinal magnetization of protons undergoing chemical exchange with the water pool Results in attenuation of the MR signal when metabolite is present and chemical exchange is slow relative to the off-resonant frequency 1 H on -NH 2 or -OH H 2 O Pool 1 H on -NH 2 or -OH H 2 O Pool Sherry & Woods, Annual Rev Biomed Eng, 2008
25 Chemical Exchange Saturation Transfer (CEST) Imaging Chemical exchange between amine protons on amine acids are a base-catalyzed process à decreasing exchange rate (k ex ) with decreasing ph Allows for separation of metabolites and a larger exchange effect at the resonant frequency of the amine proton(s)
26 Bloch-McConnell Equations
27 Bloch-McConnell Equations
28 Amine CEST EPI Harris et al., NMR Biomed 2016; 29(11):
29 Estimation of k b Initial Estimation of k b à Simulation fit to phantom data using Gaussian saturation pulses Verification of k b Estimation à Simulation using k b to phantom using Sinc3 saturation pulse (different B 1 conditions) Harris et al., NMR Biomed 2016; 29(11):
30 Simulated vs. Measured z-spectrum Z-Spectrum for Gaussian, Sinc3, and Rect Saturation Pulses à MTR asym for Gaussian, Sinc3, and Rect Saturation Pulses à Correlation between simulated and measured MTR à 50mM ph = 6.0 Harris et al., NMR Biomed 2016; 29(11):
31 Simulated z-spectrum for Brain Tumor Tissues Z-Spectrum for Normal White Matter, Glioma, and CSF à MTR asym for Normal White Matter, Glioma, and CSF à Assuming T1 and T2 for NAWM, Glioma and CSF Harris et al., NMR Biomed 2016; 29(11):
32 Effects of Saturation Parameters Pulse Train à No effect on MTR asym Effects of TR à Shorter TR = higher MTR asym Pulse Train Length + Minimum TR à 3 pulses with shortest TR Harris et al., NMR Biomed 2016; 29(11):
33 Effects of T1 and T2 Bulk water T1 and T2 à Amine proton T1 and T2 à Harris et al., NMR Biomed 2016; 29(11):
34 Effects of Glutamine Concentration 3ppm vs. ph for different concentrations à 3ppm vs. concentration for different phà Harris et al., NMR Biomed 2016; 29(11):
35 18 F-FDOPA PET FLAIR FDOPA PET FLAIR FDOPA PET
36 Measured Amine CEST - Amino Acid Phantoms Concentration = 100 mm Harris et al. Neuro Oncol 2015; 17(11):
37 Correlation with 18 F-FDOPA PET
38 Correlation with 18 F-FDOPA PET
39 FDOPA Uptake 4 6 MTRasym (%) 3.0ppm(%) F-FDOPA 1.2 Uptake Slope Describing Linear Relationship Betwen 3.0ppm and 18F-FDOPA PET Uptake in FLAIR Regions 4 2 Median = P < Compared w/ Zero -2-4 Amine CEST EPI Contrast Observed in Tumor Regions of Low vs. High 18F-FDOPA Uptake FDOPA Uptake ppm (%) MTRasym (%) 4 Slope 3.0ppm (%)/ Normalized 18F-FDOPA PET Uptake (a.u.)] Correlation with 18F-FDOPA PET P < Low 18 F-FDOPA High 18 F-FDOPA
40 Correlation with 18 F-FDOPA PET
41 Amine CEST Contrast by WHO Grade & Recurrence Average MTR asym at 3.0ppm in T2 Hyperintense Regions WHO II WHO III * * WHO IV Average MTR asym at 3.0ppm WHO II & III ** WHO IV Average MTR asym at 3.0ppm in T2 Hyperintense Regions WHO II - New WHO III - New WHO IV - New WHO II - Recurrent WHO III - Recurrent WHO IV - Recurrent ** In T2 hyperintense regions
42 C57BL/6 Murine Model with GL261 Tumor Cells MTR asym at 3.0 ppm (%) Stereotactic ph Measurements and Corresponding CEST Contrast ph Harris et al. Neuro Oncol 2015; 17(11):
43 Biopsy of Suspected Low Grade Glioma Harris et al. Neuro Oncol 2015; 17(11):
44 Biopsy of Recurrent Glioblastoma Ellingson et al. Neuro Oncol 2015; 17(11):
45 Results Image-Guided Biopsy ph (MTR asym ) Number of Strongly Positive Pixels within Tumor Area 30,000 20,000 10,000 Area of Posiitve Tumor [um 2 ] Proliferation (Ki-67) Ki-67 Stain Density vs. Amine CEST MTR asym R 2 = P = MTR asym at 3.0ppm (%) Ki-67 Positive Tumor Area vs. Amine CEST MTR asym R 2 = P = MTR asym at 3.0ppm (%) Cancer Stem Cells (CD133 + ) Number of Strongly Positive Pixels within Tumor Area Area of Posiitve Tumor [um 2 ] CD133(+) Stain Density vs. Amine CEST MTR asym R 2 = P = MTR asym at 3.0ppm (%) CD133(+) Tumor Area vs. Amine CEST MTR asym R 2 = P = MTRasym (%) Number of Strongly Positive Pixels within Tumor Area Area of Posiitve Tumor [um 2 ] Hypoxia (HIF-1alpha) HIF-1α Positive Stain Density vs. Amine CEST MTR asym R 2 = P = MTR asym at 3.0ppm (%) HIF-1α Positive Tumor Area vs. Amine CEST MTR asym R 2 = P = MTR asym at 3.0ppm (%)
46 Predictive of Radiotherapy Response Acidic Lesion Prior to Radiation Therapy N = 20 Ellingson et al. Neuro Oncol 2015; 17(11):
47 Response to Radiotherapy Change in Acidity During Radiochemotherapy N = 20 Ellingson et al. Neuro Oncol 2015; 17(11):
48 Anti-Angiogenic Agents to Modulate ph Farnsworth et al., Oncogene 2014; 33:
49 Anti-Angiogenic Agents to Modulate ph T1+C FLAIR ph Pre-Bev CEST 3ppm +5% -5% Post-Bev
50 Detection of Early Progression in Bevacizumab via ph
51 Detection of Early Progression in Bevacizumab via ph 4/20/15 (Pre-Bev) 6/1/15 (Post- Bev) 6/22/15 7/13/15 FLAIR T1+C T1 Subtraction CEST 3ppm +5% } Low ph -5% ph
52 Simultaneous ph & roef using Multi-Echo Amine CEST BOLD Effect PD-Weighted T2*-Weighted T2 -Weighted T2-Weighted Toth, J Neurooncol, 2013
53 Simultaneous ph & roef using Multi-Echo Amine CEST
54 Simultaneous ph & roef using Multi-Echo Amine CEST
55 Simultaneous ph & roef using Multi-Echo Amine CEST
56 Aerobic Glycolytic Index
57 Results AGI in Tumor vs. Normal Tissue MTR 3.0ppm(%) MR Estimate of Acidity P = rcmro MR Estimate of Relative Cerebral Metabolic Rate of Oxygen (rcmro 2 ) P < Tumor NAWM 0 Tumor NAWM Acidity (MTR 3.0ppm) and Relative Rate of Oxygen Metabolism (rcmro 2 ) MTR 3.0ppm(%) rcmro 2 Tumor NAWM MR Glycolytic Index (MTR 3ppm / rcmro 2 ) MR Glycolytic Index P < Tumor NAWM
58 Results AGI in Low and High Grade Gliomas
59 Results AGI in Low and High Grade Gliomas
60 Results Image-Guided Biopsy Aerobic Glycolytic Index (AGI) Proliferation (Ki-67) Cancer Stem Cells (CD133 + ) Hypoxia (HIF-1alpha) Number of Strongly Positive Pixels within Tumor Area 30,000 20,000 10,000 Area of Posiitve Tumor [um 2 ] Ki-67 Stain Density vs. Aerobic Glycolytic Index (AGI) R 2 = P < Aerobic Glycolytic Index (AGI) Ki-67 Positive Tumor Area vs. Aerobic Glycolytic Index (AGI) R 2 = P = Aerobic Glycolytic Index (AGI) Number of Strongly Positive Pixels within Tumor Area Area of Posiitve Tumor [um 2 ] CD133(+) Stain Density vs. Aerobic Glycolytic Index (AGI) R 2 = P = Aerobic Glycolytic Index (AGI) CD133(+) Tumor Area vs. Amine CEST MTR asym R 2 = P = MTRasym (%) Number of Strongly Positive Pixels within Tumor Area Area of Posiitve Tumor [um 2 ] HIF-1α Positive Stain Density vs. Aerobic Glycolytic Index (AGI) R 2 = P = Aerobic Glycolytic Index (AGI) HIF-1α Positive Tumor Area vs. Aerobic Glycolytic Index R 2 = P = Aerobic Glycolytic Index (AGI)
61 Results Specific to Tumor (not Inflammatory Cells) T1+C FLAIR ph AGI Tumor Cells Aerobic Glycolytic Index (AGI) vs. Tumor Cellularity R 2 = P = Aerobic Glycolytic Index (AGI) Aerobic Glycolytic Index (AGI) vs. CD45+ (Immune) Cellularity R 2 = P = CD45+ Cells Aerobic Glycolytic Index (AGI)
62 Results Treatment with Immunotherapy T1+C ph Imaging Aerobic Glycolytic Index (AGI) Pre-Treatment Post-Treatment PD-L1 mab
63 Benjamin M. Ellingson, Ph.D., M.S. Associate Professor of Radiology, Biomedical Physics, Psychiatry and Bioengineering Director, UCLA Brain Tumor Imaging Lab (BTIL) UCLA Neuro-Oncology Program Depts. of Radiological Sciences and Psychiatry David Geffen School of Medicine University of California - Los Angeles bellingson@mednet.ucla.edu
Clinical ph, Hypoxia, and Vascular Architecture MR Imaging in Human Brain Tumors
Clinical ph, Hypoxia, and Vascular Architecture MR Imaging in Human Brain Tumors Benjamin M. Ellingson, Ph.D. Director, UCLA Brain Tumor Imaging Laboratory Co-Director, UCLA Center for Computer Vision
More informationInnovative Multimodal Imaging Techniques in Brain Tumor Clinical Trials
Innovative Multimodal Imaging Techniques in Brain Tumor Clinical Trials Benjamin M. Ellingson, Ph.D. Assistant Professor of Radiology, Biomedical Physics, and Bioengineering Brain Tumor Imaging Laboratory
More informationClinical Trials for Adult Brain Tumors - the Imaging Perspective
Clinical Trials for Adult Brain Tumors - the Imaging Perspective Whitney B. Pope, M.D., Ph.D. Department of Radiology David Geffen School of Medicine at UCLA August 22, 2015 1 Disclosure of Financial Relationships
More informationIntroduction to Modern Imaging Physics and Techniques used in Clinical Neurology
Introduction to Modern Imaging Physics and Techniques used in Clinical Neurology Benjamin M. Ellingson, Ph.D., M.S. Associate Professor of Radiology, Biomedical Physics, Bioengineering, and Psychiatry
More informationEmerging contrasts at ultrahigh fields" A. Dean Sherry
Emerging contrasts at ultrahigh fields" A. Dean Sherry Advanced Imaging Research Center Department of Radiology UT Southwestern Medical Center Department of Chemistry & Biochemistry, UT Dallas ADVANCED
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationDiffusion Restriction Precedes Contrast Enhancement in Glioblastoma Multiforme
Diffusion Restriction Precedes Contrast Enhancement in Glioblastoma Multiforme Adil Bata 1, Jai Shankar 2 1 Faculty of Medicine, Class of 2017 2 Department of Diagnostic Radiology, Division of Neuroradiology,
More informationAmide Proton Transfer Imaging: A Novel MR Method for High-grade Brain Tumors.
Amide Proton Transfer Imaging: A Novel MR Method for High-grade Brain Tumors. Poster No.: C-1732 Congress: ECR 2013 Type: Scientific Exhibit Authors: M. Ida, M. Ishizuka, T. Suzuki, Y. Kubo, K. Hino, S.
More informationModeling origin and natural evolution of low-grade gliomas
Modeling origin and natural evolution of low-grade gliomas Mathilde Badoual Paris Diderot University, IMNC lab 2nd HTE workshop: Mathematical & Computer Modeling to study tumors heterogeneity in its ecosystem,
More informationMALIGNANT GLIOMAS: TREATMENT AND CHALLENGES
MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES DISCLOSURE No conflicts of interest to disclose Patricia Bruns APRN, CNS Givens Brain Tumor Center Abbott Northwestern Hospital October 12, 2018 OBJECTIVES THEN
More informationPredictive Biomarkers in GBM
Predictive Biomarkers in GBM C. David James, Ph.D. Professor & Associate Director, Brain Tumor Research Center Dept. Neurological Surgery and Helen Diller Comprehensive Cancer Center, University of California
More informationGoals for this Lecture. Case 1. Key Points MRI TECHNIQUES FOR DIFFERENTIAL DIAGNOSIS OF RECURRENT BRAIN LESIONS
MRI TECHNIQUES FOR DIFFERENTIAL DIAGNOSIS OF RECURRENT BRAIN LESIONS Goals for this Lecture 1. Review common appearances for recurrent tumor and treatment effects on conventional MRI 2. Discuss current
More information1st Annual UCLA State-of-the-Art in Neuro-Oncology
1st Annual UCLA State-of-the-Art in Neuro-Oncology Part 2 Brain and Spine Metastases: A Comprehensive, Multidisciplinary Approach Saturday, December 12, 2015 NRB Auditorium Neuroscience Research Building
More informationGlioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D)
Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D) *Neurosurgery Consultant, King Saud University, Riyadh, KSA *Adjunct Teaching Faculty, Neurosurgery, Stanford School Of Medicine,
More informationFunctional aspects of anatomical imaging techniques
Functional aspects of anatomical imaging techniques Nilendu Purandare Associate Professor & Consultant Radiologist Tata Memorial Centre Functional/metabolic/molecular imaging (radioisotope scanning) PET
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationBevacizumab: A Controversial Agent Against High-Grade Gliomas
Tumor Bevacizumab: A Controversial Agent Against High-Grade Gliomas Sussan Salas, MD 1, Miguel Guzman, MD 2, Kevin Judy, MD 1 1 Department of Neurological Surgery, Thomas Jefferson University, Philadelphia,
More informationBrain Tumors: Radiologic Perspective
Brain Tumors: Radiologic Perspective Alberto Bizzi, M.D. Neuroradiology Humanitas Research Hospital Milan, Italy The job of the neuroradiologist in the work-up of brain tumors has quite changed in the
More informationUNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD
More informationLOW GRADE ASTROCYTOMAS
LOW GRADE ASTROCYTOMAS This article was provided to us by David Schiff, MD, Associate Professor of Neurology, Neurosurgery, and Medicine at University of Virginia, Charlottesville. We appreciate his generous
More informationDosimetry, see MAGIC; Polymer gel dosimetry. Fiducial tracking, see CyberKnife radiosurgery
Subject Index Acoustic neuroma, neurofibromatosis type 2 complications 103, 105 hearing outcomes 103, 105 outcome measures 101 patient selection 105 study design 101 tumor control 101 105 treatment options
More informationPET/MR:Techniques, Indications and Applications
PET/MR:Techniques, Indications and Applications Franz Wolfgang Hirsch Professor and Head of the Department of Pediatric Radiology University Hospital Leipzig / Germany Children s Hospital University Leipzig
More informationCLASSIFICATION OF BRAIN TUMORS BASED ON MAGNETIC RESONANCE SPECTROSCOPY
CLASSIFICATION OF BRAIN TUMORS BASED ON MAGNETIC RESONANCE SPECTROSCOPY Jan Luts, Dirk Vandermeulen, Arend Heerschap, Uwe Himmelreich, Bernardo Celda, Johan A.K. Suykens, Sabine Van Huffel Department of
More informationMultiparametric imaging in oncology
Multiparametric imaging in oncology p1 T p2 p2 T T p3 p1 p3 T Marco Ravanelli Roberto Maroldi The goal of traditional imaging is high spatial and contrast resolution diagnosis, tumor extent treatment planning,
More informationIncreased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry
Neuro-Oncology Neuro-Oncology 16(3), 414 420, 2014 doi:10.1093/neuonc/not198 Advance Access date 4 December 2013 Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by
More informationOutline. Why Image Animals?
Small Animal Magnetic Resonance Imaging: Current Trends, Challenges and Perspectives for Pathological Imaging C. Chad Quarles Vanderbilt University Institute of Imaging Science Outline Why image animals?
More informationTHE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION Mustafa Rashid Issa ABSTRACT: Illustrate malignant tumors that form either in the brain or in the nerves originating in the brain.
More informationBrain Schema March 2018
Breast Cancer w/brain Mets 14 2283 / Lilly Abemaciclib PO Breast Ca or Melanoma mets allowed Leptomeningeal mets excluded Want brain met tissue Melanoma w/brain Mets 14 2209 / Bristol Myers Squibb Nivolumab
More informationDigital Washington University School of Medicine. Benjamin M. Ellingson University of California - Los Angeles
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2015 Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter,
More informationRole of DE-CT in Oncology
Role of DE-CT in Oncology Dushyant Sahani, M.D Director of CT Associate Professor of Radiology Massachusetts General Hospital Harvard Medical School Email-dsahani@partners.org Disclosure Research Grant
More informationUCLA UCLA Electronic Theses and Dissertations
UCLA UCLA Electronic Theses and Dissertations Title ph-weighted Molecular Magnetic Resonance Imaging in Gliomas Permalink https://escholarship.org/uc/item/41d3r65t Author Harris, Robert John Publication
More informationTranslating MRS into clinical benefit for children with brain tumours
Translating MRS into clinical benefit for children with brain tumours Andrew Peet NIHR Research Professor Childhood Cancer The Facts Cancer is the most common cause of death from disease in childhood Brain
More informationProc. Intl. Soc. Mag. Reson. Med. 22 (2014)
Tumor Physiology Natalie J. Serkova, PhD Department of Anesthesiology and Radiology, University of Colorado at Denver, Anschutz Medical Center, Aurora, CO This course will describe the distinct characteristics
More informationFDOPA, C11Choline, C11 Methionine. Dr K.G.Kallur
FDOPA, C11Choline, C11 Methionine Dr K.G.Kallur Why? 11C Methionine scan Had undergone resection Earlier. Post op recurrent hypercalcemia C11 Methionine Unable to see in Sestamibi scan Brain Tumor After
More informationRelationship of P53 Protein With Histopathology Degree of Intracranial Astrocytoma at Haji Adam Malik Hospital Medan
International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.10 No.15, pp 300-304, 2017 Relationship of P53 Protein With Histopathology Degree of Intracranial
More informationSURGICAL MANAGEMENT OF BRAIN TUMORS
SURGICAL MANAGEMENT OF BRAIN TUMORS LIGIA TATARANU, MD, Ph D NEUROSURGICAL CLINIC, BAGDASAR ARSENI CLINICAL HOSPITAL BUCHAREST, ROMANIA SURGICAL INDICATIONS CONFIRMING HISTOLOGIC DIAGNOSIS REDUCING TUMOR
More informationMRS and Perfusion of Brain Tumors
Department of Radiology University of California San Diego MRS and Perfusion of Brain Tumors John R. Hesselink, M.D. MRS & Perfusion of Brain Tumors Tumor histology Degree of malignancy Delineate tumor
More informationAntibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationPerfusion MRI. Youngkyoo Jung, PhD Associate Professor Radiology, Biomedical Engineering, and Clinical & Translational Science Institute
Perfusion MRI Youngkyoo Jung, PhD Associate Professor Radiology, Biomedical Engineering, and Clinical & Translational Science Institute Perfusion The delivery of blood to a capillary bed in tissue Perfusion
More informationMedia Release. Basel, 17 November 2012
Media Release Basel, 17 November 2012 Roche study showed that Avastin helped people with newly diagnosed glioblastoma live longer without their disease worsening when added to radiation and chemotherapy
More informationDeveloping a Statistical Method of Quantifying Vascular Response after Radiotherapy Co-supervised by Dr. Glenn Bauman and Dr.
6 Week Project Developing a Statistical Method of Quantifying Vascular Response after Radiotherapy Co-supervised by Dr. Glenn Bauman and Dr. Slav Yartsev Michal Stankiewicz April 9, 2013 Medical Biophysics,
More informationCNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.
CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage
More informationRoche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer
Media Release Basel, 1 June 2013 Roche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer Roche (SIX: RO, ROG; OTCQX:
More informationBrain Tumors. What is a brain tumor?
Scan for mobile link. Brain Tumors A brain tumor is a collection of abnormal cells that grows in or around the brain. It poses a risk to the healthy brain by either invading or destroying normal brain
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationAntiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. /
Antiangiogenic drugs in unresectable glioblastoma Dra. Carmen Balañá. / Outcome for unresectable GBM Overall survival for unresectable GBM without further treatment is: 3 months at most. Radiotherapy increases
More informationBone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors
Bone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors Lars Stegger, Benjamin Noto Department of Nuclear Medicine University Hospital Münster, Germany Content From PET to
More informationLiver Fat Quantification
Liver Fat Quantification Jie Deng, PhD, DABMP Department of Medical Imaging May 18 th, 2017 Disclosure Research agreement with Siemens Medical Solutions 2 Background Non-alcoholic fatty liver diseases
More informationOptimized. clinical pathway. propels high utilization of PET/MR at Pitié-Salpêtrière Hospital
Optimized propels high utilization of PET/MR at Pitié-Salpêtrière Hospital clinical pathway As one of Europe s largest teaching hospitals, Pitié-Salpêtrière Hospital is renowned for its innovative research
More informationManaging Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?
Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology
More informationRINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA
RINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA MULTIFORM GEINO 2014 Dra Estela Pineda Madrid Hospital Clínic Barcelona EGFRvIII in glioblastoma multiform The most common mutation of EGFR in GBM Expressed in 30%
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationNew Imaging Concepts in Central Nervous System Neoplasms
New Imaging Concepts in Central Nervous System Neoplasms Maarten Lequin Department of Pediatric Radiology Wilhelmina Children s Hospital/University Medical Center Utrecht New Imaging Concepts in Central
More informationUniversity of Colorado Cancer Center Brain Disease Site Schema
GBM FIRST LINE 18 0376/Kazia Phase 2a study (Part 1): A phase 2a study to evaluate the safety, pharmacokinetics and clinical activity of the PI3K/mTOR inhibitor GDC 0084 administered to patients with glioblastoma
More informationADC Values and Prognosis of Malignant Astrocytomas: Does Lower ADC Predict a Worse Prognosis Independent of Grade of Tumor?
Neuroradiology/Head and Neck Imaging Original Research Zulfiqar et al. ADC Values and Prognosis of Malignant Astrocytomas Neuroradiology/Head and Neck Imaging Original Research Maria Zulfiqar 1 David M.
More informationBrain Tumor Treatment
Scan for mobile link. Brain Tumor Treatment Brain Tumors Overview A brain tumor is a group of abnormal cells that grows in or around the brain. Tumors can directly destroy healthy brain cells. They can
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationPET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany
PET-MRI in malignant bone tumours Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany Content From PET to PET/MRI General considerations Bone metastases Primary bone tumours
More informationClinical Trials. Phase II Studies. Connective Tissue Oncology Society. Jon Trent, MD, PhD
Clinical Trials Phase II Studies Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center Connective Tissue Oncology Society GIST Overview
More informationMR Functional Imaging to Guide Radiotherapy: Challenges and Opportunities
Abstract No. 1234 MR Functional Imaging to Guide Radiotherapy: Challenges and Opportunities Michael Milosevic, MD Department of Radiation Oncology, University of Toronto Radiation Medicine Program, Princess
More informationAMERICAN BRAIN TUMOR ASSOCIATION. Oligodendroglioma and Oligoastrocytoma
AMERICAN BRAIN TUMOR ASSOCIATION Oligodendroglioma and Oligoastrocytoma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the
More informationStaging Colorectal Cancer
Staging Colorectal Cancer CT is recommended as the initial staging scan for colorectal cancer to assess local extent of the disease and to look for metastases to the liver and/or lung Further imaging for
More informationAMERICAN BRAIN TUMOR ASSOCIATION. Oligodendroglioma and Oligoastrocytoma
AMERICAN BRAIN TUMOR ASSOCIATION Oligodendroglioma and Oligoastrocytoma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the
More informationCitation Pediatrics international (2015), 57.
Title Long-term efficacy of bevacizumab a pediatric glioblastoma. Umeda, Katsutsugu; Shibata, Hirofum Author(s) Hiramatsu, Hidefumi; Arakawa, Yoshi Nishiuchi, Ritsuo; Adachi, Souichi; Ken-Ichiro Citation
More informationCRIPTO-1 A POSSIBLE NEW BIOMARKER IN GLIOBLASTOMA MULTIFORME PIA OLESEN, MD, PHD STUDENT
CRIPTO-1 A POSSIBLE NEW BIOMARKER IN GLIOBLASTOMA MULTIFORME PIA OLESEN, MD, PHD STUDENT Glioblastoma WHO Grade IV Glioma Heterogenic Undiffenrentiated phenotype 50% of all Gliomas Around 600 patients
More informationAdvancement in molecular tumor diagnosis
3D APT whitepaper MR clinical applications Amide Proton Transfer weighted imaging: Advancement in molecular tumor diagnosis Kim van de Ven, PhD ; Jochen Keupp, PhD 2 Senior Clinical Scientist, Philips
More informationChemotherapy in malignant brain tumors
Chemotherapy in malignant brain tumors Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH 4031 Basel zimmermannf@uhbs.ch Tumor types Neuro-epithelial tumors - Glioblastoma
More informationPrinciples of nuclear metabolic imaging. Prof. Dr. Alex Maes AZ Groeninge Kortrijk and KULeuven Belgium
Principles of nuclear metabolic imaging Prof. Dr. Alex Maes AZ Groeninge Kortrijk and KULeuven Belgium I. Molecular imaging probes A. Introduction - Chemical disturbances will precede anatomical abnormalities
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationNeuro-Oncology Program
Neuro-Oncology Program The goals of the Neuro-oncology Committee are: 1) to improve duration and quality of life of brain tumor patients; 2) to assess disease and treatment-related effects on neurocognitive
More informationOligodendrogliomas & Oligoastrocytomas
Oligodendrogliomas & Oligoastrocytomas ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely
More informationIt s s Always Something!
It s s Always Something! New Approaches in Brain Tumor Treatment Virginia Stark-Vance, M.D. When Something Is a Brain Tumor Brain tumors aren t rare: there are over 100,000/yr Most originate as other cancers
More informationOff-Label Treatments. Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease. Outline
Off-Label Treatments Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease Jennifer Clarke, MD, MPH Assistant Professor Division of Neuro-Oncology Depts of Neurological
More informationMagnetic Resonance Imaging for Prediction and Assessment of Treatment Response in Bevacizumab-Treated Recurrent Glioblastoma
Magnetic Resonance Imaging for Prediction and Assessment of Treatment Response in Bevacizumab-Treated Recurrent Glioblastoma The Harvard community has made this article openly available. Please share how
More informationThe Angiopoietin Axis in Cancer
Ang2 Ang1 The Angiopoietin Axis in Cancer Tie2 An Overview: The Angiopoietin Axis Plays an Essential Role in the Regulation of Tumor Angiogenesis Growth of a tumor beyond a limiting size is dependent upon
More informationIncidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide
405 Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide Walter Taal, MD 1 Dieta Brandsma, MD, PhD 1 Hein G. de Bruin, MD, PhD
More informationIntravenous Delivery of Toca 511 in Patients With High Grade Glioma Results in Quantifiable Expression of Cytosine Deaminase in Tumor Tissue
Intravenous Delivery of Toca 511 in Patients With High Grade Glioma Results in Quantifiable Expression of Cytosine Deaminase in Tumor Tissue Tobias Walbert, 1 Daniela Bota, 2 Michael A Vogelbaum, 3 Steven
More informationImaging and radiotherapy physics topics for project and master thesis
Imaging and radiotherapy physics topics for project and master thesis Supervisors: Assoc. Professor Kathrine Røe Redalen and PhD candidates Franziska Knuth and Kajsa Fridström. Contact: kathrine.redalen@ntnu.no,
More informationNeuroblastoma. Elizabeth Roberts. Data Coordinator CIBMTR Data Managers Mentor. Tandem Meeting February 18
Neuroblastoma Elizabeth Roberts Data Coordinator CIBMTR Data Managers Mentor Tandem Meeting February 18 Objectives Know what neuroblastoma is, how it is diagnosed, and how it is treated Complete form 2026:
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More informationImaging: When to get MRI, CT or PET-CT?
Imaging: When to get MRI, CT or PET-CT? Alina Uzelac, D.O. Assistant Clinical Professor Neuroradiology UCSF Department of Radiology and Biomedical Imaging San Francisco General Hospital Overview CT MRI
More informationConcepts for a personalized neurosurgical oncology. XXIV Annual Conference Pietro Paoletti 27. November 2015
Concepts for a personalized neurosurgical oncology Jörg-Christian Tonn Dept. of Neurosurgery Ludwig-Maximilian University München Großhadern Germany XXIV Annual Conference Pietro Paoletti 27. November
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationLead Supervisor 1: Physics Supervision Name: Matthew Grech-Sollars Institution/Department: Imperial College London: Department of Surgery & Cancer
Project Title: Development of MRI brain tumour fingerprinting for clinical assessment of brain tumour biology Lead Supervisor 1: Physics Supervision Name: Matthew Grech-Sollars Institution/Department:
More informationThe Paul Evans Memorial Lecture Functional radiotherapy targeting using focused dose escalation. Roberto Alonzi Mount Vernon Cancer Centre
The Paul Evans Memorial Lecture Functional radiotherapy targeting using focused dose escalation Roberto Alonzi Mount Vernon Cancer Centre Overview Introduction and rationale for focused dose escalation
More informationDurable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment
Durable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment Cloughesy TF 1, Landolfi J 2, Vogelbaum MA 3, Ostertag D 4, Elder JB 5, Bloomfield S
More informationMolecular Imaging in the Development of Cancer Therapeutics. Johannes Czernin
Molecular Imaging in the Development of Cancer Therapeutics Johannes Czernin Ahmanson Biological Imaging Division University of California Los Angeles Cancer Statistics Cancer Type 5-year Survival Rate
More informationTUMOR HYPOXIA BENCH TO BEDSIDE
TUMOR HYPOXIA BENCH TO BEDSIDE Marianne Nordsmark, Lise Saksø Mortensen, Morten Busk, Michael Horsman, Markus Alber, Niels Bassler, Jørgen Petersen and Jens Overgaard. Dept. Oncology, Aarhus University
More informationPatterns of Brain Tumor Recurrence Predicted From DTI Tractography
Patterns of Brain Tumor Recurrence Predicted From DTI Tractography Anitha Priya Krishnan 1, Isaac Asher 2, Dave Fuller 2, Delphine Davis 3, Paul Okunieff 2, Walter O Dell 1,2 Department of Biomedical Engineering
More informationSociety for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationThe Effect of Zn2+ Binding on the Chemistry of Tm3+ and Eu3+ Chelates
Portland State University PDXScholar University Honors Theses University Honors College 3-1-2018 The Effect of Zn2+ Binding on the Chemistry of Tm3+ and Eu3+ Chelates Diana King Portland State University
More informationAdult Central Nervous System Tumors Treatment (PDQ )
1 di 20 28/06/2016 11.18 NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute
More informationImmunotherapy for Malignant Brain Cancer: Overcoming Immune Suppression to Improve the Clinical Experience
Immunotherapy for Malignant Brain Cancer: Overcoming Immune Suppression to Improve the Clinical Experience Derek Wainwright, PhD Assistant Professor Departments of Neurological Surgery, Microbiology-Immunology
More informationLactate Chemical Exchange Saturation Transfer (LATEST) Imaging in vivo: A. Biomarker for LDH Activity
Lactate Chemical Exchange Saturation Transfer (LATEST) Imaging in vivo: A Biomarker for LDH Activity Catherine DeBrosse 1, Ravi Prakash Reddy Nanga 1, Puneet Bagga 1, Kavindra Nath 2, Mohammad Haris 3,
More informationGeneral Identification. Name: 江 X X Age: 29 y/o Gender: Male Height:172cm, Weight: 65kg Date of admission:95/09/27
General Identification Name: 江 X X Age: 29 y/o Gender: Male Height:172cm, Weight: 65kg Date of admission:95/09/27 Chief Complaint Sudden onset of seizure for several minutes Present illness This 29-year
More informationMagnetization Preparation Sequences
Magnetization Preparation Sequences Acquisition method may not give desired contrast Prep block adds contrast (and/or encoding) MP-RAGE = Magnetization prepared rapid acquisition with gradient echo (Mugler,
More informationMRI/MRS Biomarkers. Robert E. Lenkinski, Ph.D.
MRI/MRS Biomarkers Robert E. Lenkinski, Ph.D. Disclosure GE Healthcare-Research Grant Aspect MR-Scientific Advisor Aposense-Scientific Advisor Brainwatch-Scientific Advisor I will be discussing off-label
More informationPediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
More information